Please login to bookmark Close

Pfizer has lost a patent infringement lawsuit against Samsung Bioepis over the generic version of its blockbuster autoimmune drug Enbrel, with a judge finding all but one of the patent’s claims is invalid. 

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au